InMed Pharmaceuticals Inc
NASDAQ:INM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
InMed Pharmaceuticals Inc
NASDAQ:INM
|
CA |
|
S
|
Sappi Ltd
JSE:SAP
|
ZA |
|
NextPlat Corp
NASDAQ:NXPL
|
US |
|
K
|
Kronologi Asia Bhd
KLSE:KAB
|
MY |
|
B
|
Bigtincan Holdings Ltd
OTC:BTGHF
|
AU |
|
I
|
IBF Financial Holdings Co Ltd
TWSE:2889
|
TW |
|
M
|
McDonald's Corp
SGO:MCD
|
US |
|
SML Mahindra Limited
NSE:SMLMAH
|
IN |
|
R
|
RH Bophelo Ltd
JSE:RHB
|
ZA |
|
S
|
Satra Properties (India) Ltd
BSE:508996
|
IN |
|
I
|
ISC Co Ltd
KOSDAQ:095340
|
KR |
|
T
|
Thanh Dat Investment Development JSC
VN:DTD
|
VN |
|
C
|
City Service SE
WSE:CTS
|
LT |
|
Meta Data Ltd
NYSE:AIU
|
CN |
|
Jefferies Financial Group Inc
NYSE:JEF
|
US |
|
Af Gruppen ASA
OSE:AFG
|
NO |
|
Europris ASA
OSE:EPR
|
NO |
|
S
|
Safe Bulkers Inc
NYSE:SB
|
MC |
|
J
|
Jet Airways (India) Ltd
NSE:JETAIRWAYS
|
IN |
|
A
|
Astera Labs Inc
NASDAQ:ALAB
|
US |
InMed Pharmaceuticals Inc
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm is developing a pipeline of prescription-based products targeting treatments for diseases with unmet medical needs as well as developing manufacturing technologies. The company is specializing in the research and development of cannabinoid-based therapies and a system for the manufacturing of pharmaceutical-grade cannabinoids. The company is also developing an integrated biosynthesis-based manufacturing approach, called IntegraSyn, for synthesizing pharmaceutical-grade cannabinoids, for potential use in product candidates. The firm's two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides direct neuroprotection and reduce intraocular pressure in the eye.
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm is developing a pipeline of prescription-based products targeting treatments for diseases with unmet medical needs as well as developing manufacturing technologies. The company is specializing in the research and development of cannabinoid-based therapies and a system for the manufacturing of pharmaceutical-grade cannabinoids. The company is also developing an integrated biosynthesis-based manufacturing approach, called IntegraSyn, for synthesizing pharmaceutical-grade cannabinoids, for potential use in product candidates. The firm's two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides direct neuroprotection and reduce intraocular pressure in the eye.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
